Q4 whale (big fish) activity was released mid-month. Some interesting OGXI activity:
Jeffrey R Jay (Great Point Partners), the fourth largest OGXI shareholder, increased his OGXI position by 101,383 shares (+14%) and held 822,492 shares as of 12/31/12. Jay's history isn't perfect , but he has a good track record and his credentials are respectable.
RA Capital Management purchased 370,807 shares in Q4 (+70%) and became OGXI's second largest shareholder with 894,232 shares on 12/31/12. I believe RA's biotech stock picker is Peter Kolchinsky, who has a PhD from Harvard and a good track record, as well.
As of 12/31/12, OGXI was about 10% of Jay's portfolio and a little more than 4% of that of RA. I'm actually surprised that they'd be buying OGXI ahead of 011 P3 news (which I think will be disappointing), but their timing certainly suggests it.
jd, I've only been doing this for a few years (6?) and I'm more of a gambler than investor. I put a lot of resources into understanding SNUS and trying to glean anecdotal info from their various trials and company disclosures. We even stumbled on a blog that was meant for SNUS trial patients (only?) and was just fooled enough to take a slightly larger position (2x) than I normally would have. If I recall correctly, SNUS' last P3 missed statistical significance by 1%. (That stings a little even years after the fact, lol)
You opine, "I'm actually surprised that they'd be buying OGXI ahead of 011 P3 news (which I think will be disappointing)," Since we already have encouraging news about overall efficacy of ANS 2nd generation (or 1.5) I am curious as to the source of your pessimism. I own a piece of OGXI and am encouraged by recent events that did not occur in anyone's bedroom (surely company execs don't shag in the broom closet...). Can you provide a little color concering your comment?